PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/633,762 TRANSMITTAL Filing Date August 4, 2003 FORM First Named Inventor Fred Hassan Art Unit 1614 (to be used for all correspondence after initial filing) **Examiner Name** Attorney Docket Number 00860.US1 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance communication Fee Transmittal Form Drawing(s) to Group Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to Group Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final **Provisional Application** Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Terminal Disclaimer Extension of Time Request Identify below): A return-receipt postcard is enlosed. Request for Refund **Express Abandonment Request International Search Paper** CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Individuat name Pharmacia & Upjohn Company Signature Date **CERTIFICATE OF TRANSMISSION/MAILING** I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Typed or printed name Julie K. Lyons Date relie K February 18, 2004 Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

					Atty. Docket No. 00860.US1			Serial No. 10/633,762					
			3370T	e CITED B	y ap	PLICANT				<u></u>			
LIST OF REFERENCES CITED BY APPLICANT							Applicant Fred Hassan			Group			
/ · .	3 2001	الله و	1				Fili	ng Date 8/04/2003			<u> </u>		
FEB 1	, •	A GFE				TIC DATE	ENT I	OOCUMENTS	τ			Filing Date	
SAJENT &	RADEN					U.S. I AII	T		Clas	s Su	bclass	If Appropriate	
	1	T		eument		Date		Name		24	8.58		1
Examiner Initial	_	$\rightarrow$		umber		January 8, 1979		Melloni et al.		1	49		-
	A	A		9,449		ne 11, 1990		elloni et al.	54	1 1	74		-
	A	В	<u> </u>	8,433		pril 12, 1994		Ielloni et al.	51	-	223.5		-
	P	C		91,735	1	pril 28, 1995		Anthony S. dePadova	51		567	and the second	
		AD		53,651		July 21, 2000		Thomas J. Guttuso			220		
		AE		10,098B1				Seth Lederman					
		AF	6,3	358,944B1		FOREIGN	I PA	TENT DOCUMENTS	-	Class	Subcla		
-	Date							Country					
-				ocument Iumber			1				-1/00		
								World		A61K	31/00		
		AC		WO 01/01973	A2	June 22, 2000		World		A61K	31/13		
		A		WO 02/4000		November 6, 200		World		A61K			
-		+-	-	WO 02/0786	_	March 15, 2002		World		C07D		200	
		711 02/000699			A1 June 21, 2002		World		A61F		19	go traff	
-	710 02/039598		_	November 5, 200				A61F		00	4.6		
-	1 1 9'					November 27,	ART (Including Author, Title, Date, Pertinent Pages, Etc.)  ann, PhD," Biochemical, metabolic, and vascular mechanisms in menopausal hot  be a second to the sweating threshold in symptomatic but not in						
-		ئلــ	AL	1	C	THER PRIOR AR	T (Inc	luding Author, 1111	, and v	ascula	r mecha	nisms in menopeear	
-		-		XP-001170	3734 R	obert R. Freedman	n, Ph	)," Blochemear,			old in S	symptomatic but not	, in
	flashes, vio 2												
-	asymptomates Promise for Hot Flashes in Brease Car								ww.medicine-news.c				
L													
AO XP-002263134 The AP XP-002936123 "Reboxetine", 1999 65-83.  AP XP-002936123 "Reboxetine", 1999 65-83.								010810					
	AQ XP-008025613 "Hot Flushes: Mechanism and 1989. Alan R. Liss, Inc.  AR C. L. Loprinzl et al, "Venlafaxine in Management of Hot Flashes in Survivors of Breast Cancer: a Rand Cantrolled Trial", The Lancet V356 December 16, 2000.								et Cancer: a Randoi	mised			
_ Γ													
1													
1			A	S Kathle	en L. l	Pritchard, "Hormo 62.	ne Re	placement in Women and	orating	Tamo	ifen-Inc	luced Hot Flashes",	Journ
	AS Kathleen L. Pritchard, "Hormone Replacement in Women war every 2001;6:353-362.  AT Richard M. Goldberg et al, "Transdermal Clonidine for Ameliorating Tamoxifen-Induced Hot Flashe												

	Listo	REFE	ERENCES CITED BY APPLICANT Use several sheets if necessary)		Docket No. 0860.US1	Serial No. 10/633,762				
<b>′</b>	3 3 200	الة <sub>4</sub>	:	Applicant Fred Hassan						
A C	FEB 2	AT ST		Filing Date	8/04/2003	Group				
	& TRAUE	Clinical Oncology V12 No. 1 (January), 1994 155-158.  AU Larry R. Laufer et al, "Effect of Clonidine on Hot Flashes in Postmenopausal Women", V60 No.5( November 1982.  AV B.E. Leonard, "Noradrenaline in basic models of depression", European Neuropsychopharmacology 7 Suppt 1997 S11-S16.								
,										
	_									
	AW Charles L. Loprinzl et al., "Pilot Evaluation of Venlafaxine Hydrochloride for the Therapy of Hot Flas Cancer Survivors", Journal of Clinical Oncology, V16, No. 7 (July) 1998 pp 2377-2381.									
		AX	V. Stearns et al, "A Pilot Trial Assessing the efficacy of Paroxetine Hydrochloride (Paxil) in controlling hot flashe in breast cancer survivors", Annals of Oncology 11: 17, 2000.							
	Examiner			Date Consider	ed					